Alzheimer’s Disease Biomarkers &Clinical Trials Insight 2028 Report Highlights:
- Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
- Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
- Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
- Alzheimer’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample: http://biomarkersinsights.com/alzheimers-disease-biomarkers-and-clinical-trials-insight-2028
Alzheimer disease is a neurodegenerative disorder that progressively compromises cognition, function, and behavior. In recent years, the major focus of pharmaceutical companies has shifted towards the development of novel biomarkers which are the biological markers that measures biological state. These biomarkers can help characterize a baseline state, a disease process, or response to treatment. Biomarkers include measures of genes, omics technologies, imaging, blood, electrocardiograms, or evaluations of organ function. The wide range of applications associated with research with biomarker has led to development of robust clinical pipeline of biomarkers. ,/p>
Recently, researchers have identified a potential biomarker for Alzheimer’s disease diagnosis that may also serve as a therapeutic target. The research study demonstrated that levels of pro-resolving lipid mediators were correlated with severity of cognition impairment –the greater the severity, the lower the levels of the lipid mediators that resolve inflammation. They also found a relationship between cognition impairment severity and pro-inflammatory lipid mediators – the greater the degree of cognition impairment, the higher the levels of the lipid mediators that promote inflammation. These findings have led to identification of lipid mediators as potential biomarker and target which can slow the onset of the Alzheimer disease. Apart from this, several other clinical trials are ongoing which are evaluating other potential biomarkers that are expected to enter the market during the forecast period.
Biomarkers also have a critical role in the development of precision drugs for the Alzheimer disease as they aid researchers enroll the right patients in clinical trials and track their progress. For instance, the Amyvid PET scan, a biomarker that was developed with early funding from the ADDF, was a critical component of the phase 3 trials that led to approval of Aduhelm, the first new Alzheimer’s drug in 17 years. The US FDA approved Aduhelm based on biomarker data from patient scans showing rapid clearance of amyloid plaques from patients’ brains. Apart from this, two other drugs that received FDA breakthrough designation including lecanemab (Eisai and Biogen) and donanemab (Eli Lilly) have also used the Amyvid PET scan work to measure reductions in amyloid deposits in the brain. Our report provides in-depth analysis on the biomarkers associated with the precision therapy development across various stages of clinical trials.
As per our report findings, the global Alzheimer drug biomarker is expected to surpass US$ 5 Billion by 2028 which is mainly attributed to the increase in prevalence of Alzheimer disease. Rising life expectancy is contributing to quick increases in the number of the aged population. In addition, is associated with increased prevalence of chronic diseases like dementia. Furthermore, several key players in the market are now more focused on setting-up effective joint ventures, acquisitions, and/or collaborations in order to expand their respective consumer bases. By doing so, they stand to boost their given target bases by being able to cater to them on both a global as well as domestic level. These factors are anticipated to boost the growth of global Alzheimer biomarker market during the forecast period. Owing to the presence of many noteworthy players, US is projected to be witnessing a larger share of the overall market as compared to the other regions. A number of research and development projects are carried out in various areas of US and academic universities have also received the fund provided by the government in order to undertake research.
The report provides in-depth analysis on biomarkers which are present in clinical trials across various drugs for Alzheimer disease. Our report provides a comprehensive overview of the global Alzheimer biomarker market and detailed information on factors that will fuel or hamper market growth during the forecast period 2022-2028. Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.
Contact:
Sussan
Research Partner
Biomarkers Insights
sample@biomarkersinsights.com